👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Citi restarts coverage of Eli Lilly with Buy rating on increased tirzepatide forecasts

Published 2024/09/13, 19:08
© Reuters
LLY
-

Citi reinstated its coverage of Eli Lilly & Co. (NYSE:LLY) with a Buy rating and a target price of $1,060 per share in a note Friday.

The move follows a period during which the rating was suspended. The analysts at Citi have updated their projections for Eli Lilly, driven by enhanced forecasts for the company's tirzepatide, a treatment for diabetes and obesity.

According to Citi, the increased forecasts for tirzepatide are based on recent sales data, prescription trends, and updated company guidance.

"Our non-GAAP EPS forecasts increase accordingly by up to 19% for 2024-27 and 9-15% thereafter for the forecast period," Citi wrote.

The firm's analysis includes a broad range of valuations, with a bull-bear valuation range of $1,283 to $692 per share.

Citi's note highlights that the competitive landscape for diabetes and obesity treatments has shifted.

The analysts see a "diminished competitive threat from Roche’s oral GLP-1 CT-996," citing issues such as elevated heart rates and high nausea incidence associated with the treatment. This assessment is based on a small study with high variability.

The resumption of coverage and the bullish rating also reflect Citi's preference for Eli Lilly among major U.S. pharmaceutical companies.

The firm ranks Eli Lilly alongside Merck (MRK) as preferred stocks in the U.S. market and includes Novo Nordisk, Sanofi, GlaxoSmithKline (GSK), and UCB among its favored European stocks.

Overall, Citi's updated outlook underscores confidence in Eli Lilly's future performance, particularly given the promising developments in its diabetes and obesity treatments

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.